Evidence map›Paper›PMID 42358982›Full record

ArticleFrontiers in immunology2026

CD25

Arimelek Cortés-Hernández, Saúl Arteaga-Cruz, Iyari I Martínez Iturbe, Katya Rosas-Cortina, Marco A Vigil Mora, Erick Legorreta-Anguiano, Judith E Reyes Barrientos, Evelyn K Álvarez-Salazar, Alejandra Cervera, Beatriz E Sánchez-Hernández and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Arimelek Cortés-HernándezDepartment of Immunology, Biomedical Research Institute, National Autonomous University of Mexico, Mexico City, Mexico.
Saúl Arteaga-CruzDepartment of Immunology, Biomedical Research Institute, National Autonomous University of Mexico, Mexico City, Mexico.
Iyari I Martínez IturbeDepartment of Immunology, Biomedical Research Institute, National Autonomous University of Mexico, Mexico City, Mexico.
Katya Rosas-CortinaDepartment of Immunology, Biomedical Research Institute, National Autonomous University of Mexico, Mexico City, Mexico.
Marco A Vigil MoraDepartment of Immunology, Biomedical Research Institute, National Autonomous University of Mexico, Mexico City, Mexico.
Erick Legorreta-AnguianoDepartment of Immunology, Biomedical Research Institute, National Autonomous University of Mexico, Mexico City, Mexico.
Judith E Reyes BarrientosDepartment of Immunology, Biomedical Research Institute, National Autonomous University of Mexico, Mexico City, Mexico.
Evelyn K Álvarez-SalazarDepartment of Immunology, Biomedical Research Institute, National Autonomous University of Mexico, Mexico City, Mexico.
Alejandra CerveraBiomedical Genomics and Bioinformatics Laboratory, Instituto Nacional de Ciencias Genómicas, Mexico City, Mexico.
Beatriz E Sánchez-HernándezDepartment of Pathology, Instituto Nacional de Ciencias Médicas y la Nutrición Salvador Zubirán, Mexico City, Mexico.
Armando Gamboa DomínguezDepartment of Pathology, Instituto Nacional de Ciencias Médicas y la Nutrición Salvador Zubirán, Mexico City, Mexico.
Gloria SoldevilaDepartment of Immunology, Biomedical Research Institute, National Autonomous University of Mexico, Mexico City, Mexico.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The clinical translation of alloantigen-specific regulatory T cells (AS-Tregs) is constrained by their low frequency in peripheral blood, limited purity, and functional instability following prolonged

Indexed as

CD27 LigandIsoantigensT-Lymphocytes, RegulatoryCells, CulturedDendritic CellsHumansImmunotherapyInterleukin-2 Receptor alpha SubunitTumor Necrosis Factor Receptor Superfamily, Member 7CD27 LigandInterleukin-2 Receptor alpha SubunitIsoantigensTumor Necrosis Factor Receptor Superfamily, Member 7adoptive cell therapyalloantigen-specific TregsCD27lineage stabilitytransplantation

Identifiers

PMID42358982
PMCPMC13290811

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.